Cogstate Limited (CGS.AX)
ASX · AUD · Healthcare · Health Information Services
A$3.42 (-1.44%) as of
Key statistics
- Market cap
- 588.67M
- P/E (TTM)
- 34.20
- Forward P/E
- 21.35
- EPS (TTM)
- 0.1000
- Dividend yield
- 1.15%
- 52-week range
- 1.7500 – 3.9800
- Beta
- 0.27
- Revenue (TTM)
- 60.86M
- Profit margin
- 19.54%
- Analyst target
- A$4.50
- Volume
- 62.59k
About Cogstate Limited
Cogstate Limited, a neuroscience solutions company, engages in the creation, validation, and commercialization of digital brain health assessments worldwide. The company offers digital cognitive assessment, endpoint data quality (rater services), remote assessment, scientific consulting, healthcare cognitive screening, and research and academic collaboration solutions for various therapeutic areas, including Alzheimer's disease and dementia, preclinical Alzheimer's disease, pediatrics and rare disease, Parkinson's disease, multiple sclerosis, schizophrenia, oncology, safety, and sleep and mood disorders. It also designs and provides quality assurance services in clinical trials focused on the administration, scoring, and recording of conventional brain health assessments. In addition, it develops a tool for primary care physicians and/or hospitals to assess cognitive decline. Its technology and associated services are used to quantify the effect of disease and drugs, devices, or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The company serves biopharmaceutical companies, academic institutions, physicians, and patients. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Health Information Services
- Headquarters
- Melbourne, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.